22 December 2020 Post Importation Testing Exemptions (PITE) granted due to COVID-19 pandemic Post importation testing exemption approvals granted since March 2020 due to the Covid-19 pandemic, are extended to 30 April 2021 without further need of an application thereof. The initial approval date was extended to...
Pretoria, 4 November 2026 – The South African Health Products Regulatory Authority (SAHPRA) is joining the global #MedSafetyWeek campaign, running from 2 - 8 November. This campaign aims to encourage patients and healthcare professionals to report suspected side effects of medicines, supporting ongoing medicine-safety monitoring...
19 October 2026 – “I knew about SAHPRA as a regulator, but I did not know about the Radiation Control Unit and the work they do,” reflected a final-year BSc student during the University of North West (NWU)’s School of Physical and Chemical Sciences (SPCS)...
02 October 2026 – The South African Health Products Regulatory Authority (SAHPRA) wishes to alert all stakeholders to phishing emails currently circulating with the subject lines “Urgent” and “Follow-Up”. SAHPRA is aware that some stakeholders have already clicked on links contained in these emails. Stakeholders who have...
18 September 2026 – The South African Health Products Regulatory Authority (SAHPRA) is participating in the 70th International Atomic Energy Agency (IAEA) General Conference in Vienna, underscoring its critical role in ensuring the safe and responsible use of radiation in healthcare. At the conference, SAHPRA contributed...
14 September 2026 – The South African Health Products Regulatory Authority (SAHPRA) hosted a three-day bilateral engagement with Lesotho’s Radiation Protection Agency (RPA) at its Pretoria head office. The meeting promoted knowledge sharing in radiation regulation and regulatory excellence, with the RPA delegation comprising executive...
26 August 2026 – The South African Health Products Regulatory Authority (SAHPRA) is pleased to share that the World Health Organization (WHO) has confirmed that South Africa has achieved and maintained Maturity Level 3 (ML3) for the regulation of vaccines (producing), as of 18 August...
20 August 2026 – The South African Health Products Regulatory Authority (SAHPRA) wishes to reaffirm the public that routine childhood vaccines used in South Africa remain safe based on ongoing evidence and monitoring. SAHPRA continuously monitors the safety and quality of vaccines used in South Africa....
20 August 2026 The South African Health Products Regulatory Authority (SAHPRA) wishes to remind healthcare professionals of the risk of angioedema during treatment with angiotensin-converting enzyme (ACE) inhibitors (e.g. captopril, enalapril, lisinopril, perindopril, quinapril, ramipril, trandolapril). Healthcare professionals are reminded that ACE inhibitor treatment should be...
Pretoria, 17 August 2026 – Tshwane University of Technology (TUT) Faculty of Science students at the Arcadia Campus filled the Science Hall to welcome the South African Health Products Regulatory Authority (SAHPRA) as part of its ongoing programme to engage university students and raise...
Pretoria, 16 August 2026 – The South African Health Products Regulatory Authority (SAHPRA) has initiated the recall of four batches of Enalapril 10mg Arya, a medicine commonly used to treat high blood pressure (hypertension), following the identification of out-of-specification results during post-marketing surveillance inspections. The recall...
